144 related articles for article (PubMed ID: 17255303)
1. Biological aspects and binding strategies of vascular endothelial growth factor in renal cell carcinoma.
Rini BI; Rathmell WK
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):741s-746s. PubMed ID: 17255303
[TBL] [Abstract][Full Text] [Related]
2. Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene.
Liu MY; Poellinger L; Walker CL
Cancer Res; 2003 May; 63(10):2675-80. PubMed ID: 12750296
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of vascular endothelial growth factor in renal cell carcinoma cells by glucocorticoids.
Iwai A; Fujii Y; Kawakami S; Takazawa R; Kageyama Y; Yoshida MA; Kihara K
Mol Cell Endocrinol; 2004 Oct; 226(1-2):11-7. PubMed ID: 15489000
[TBL] [Abstract][Full Text] [Related]
4. The role of vascular endothelial growth factor in kidney and prostate cancer.
Delongchamps NB; Peyromaure M
Can J Urol; 2007 Oct; 14(5):3669-77. PubMed ID: 17949520
[TBL] [Abstract][Full Text] [Related]
5. Comparative analysis of COX-2, vascular endothelial growth factor and microvessel density in human renal cell carcinomas.
Hemmerlein B; Galuschka L; Putzer N; Zischkau S; Heuser M
Histopathology; 2004 Dec; 45(6):603-11. PubMed ID: 15569051
[TBL] [Abstract][Full Text] [Related]
6. Expression of Ets-1 in human clear cell renal cell carcinomas: implications for angiogenesis.
Mikami S; Oya M; Mizuno R; Murai M; Mukai M; Okada Y
Cancer Sci; 2006 Sep; 97(9):875-82. PubMed ID: 16856880
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of vascular endothelial growth factor expression in clear cell renal cell carcinoma.
Djordjevic G; Mozetic V; Mozetic DV; Licul V; Ilijas KM; Mustac E; Oguic R; Fuckar Z; Jonjic N
Pathol Res Pract; 2007; 203(2):99-106. PubMed ID: 17270362
[TBL] [Abstract][Full Text] [Related]
8. Different vascular endothelial growth factor (VEGF), VEGF-receptor 1 and -2 mRNA expression profiles between clear cell and papillary renal cell carcinoma.
Ljungberg BJ; Jacobsen J; Rudolfsson SH; Lindh G; Grankvist K; Rasmuson T
BJU Int; 2006 Sep; 98(3):661-7. PubMed ID: 16925769
[TBL] [Abstract][Full Text] [Related]
9. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma.
Bates DO; Cui TG; Doughty JM; Winkler M; Sugiono M; Shields JD; Peat D; Gillatt D; Harper SJ
Cancer Res; 2002 Jul; 62(14):4123-31. PubMed ID: 12124351
[TBL] [Abstract][Full Text] [Related]
10. The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma.
Choueiri TK; Bukowski RM; Rini BI
Semin Oncol; 2006 Oct; 33(5):596-606. PubMed ID: 17045089
[TBL] [Abstract][Full Text] [Related]
11. The relationship of vascular endothelial growth factor and coagulation factor (fibrin and fibrinogen) expression in clear cell renal cell carcinoma.
Verheul HM; van Erp K; Homs MY; Yoon GS; van der Groep P; Rogers C; Hansel DE; Netto GJ; Pili R
Urology; 2010 Mar; 75(3):608-14. PubMed ID: 19683801
[TBL] [Abstract][Full Text] [Related]
12. Opportunities and obstacles to combination targeted therapy in renal cell cancer.
Sosman JA; Puzanov I; Atkins MB
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):764s-769s. PubMed ID: 17255307
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor expression is increased in renal cell carcinoma.
Nicol D; Hii SI; Walsh M; Teh B; Thompson L; Kennett C; Gotley D
J Urol; 1997 Apr; 157(4):1482-6. PubMed ID: 9120987
[TBL] [Abstract][Full Text] [Related]
14. Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function.
Patel NS; Li JL; Generali D; Poulsom R; Cranston DW; Harris AL
Cancer Res; 2005 Oct; 65(19):8690-7. PubMed ID: 16204037
[TBL] [Abstract][Full Text] [Related]
15. Interferon-alpha inhibits in vitro osteoclast differentiation and renal cell carcinoma-induced angiogenesis.
Avnet S; Cenni E; Perut F; Granchi D; Brandi ML; Giunti A; Baldini N
Int J Oncol; 2007 Feb; 30(2):469-76. PubMed ID: 17203230
[TBL] [Abstract][Full Text] [Related]
16. Understanding the importance of smart drugs in renal cell carcinoma.
Patard JJ; Rioux-Leclercq N; Fergelot P
Eur Urol; 2006 Apr; 49(4):633-43. PubMed ID: 16481093
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.
Albiges L; Salem M; Rini B; Escudier B
Hematol Oncol Clin North Am; 2011 Aug; 25(4):813-33. PubMed ID: 21763969
[TBL] [Abstract][Full Text] [Related]
18. Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma.
Flaherty KT; Puzanov I
Biochem Pharmacol; 2010 Sep; 80(5):638-46. PubMed ID: 20382128
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model.
Verheul HM; Hammers H; van Erp K; Wei Y; Sanni T; Salumbides B; Qian DZ; Yancopoulos GD; Pili R
Clin Cancer Res; 2007 Jul; 13(14):4201-8. PubMed ID: 17634549
[TBL] [Abstract][Full Text] [Related]
20. Different isoform patterns for vascular endothelial growth factor between clear cell and papillary renal cell carcinoma.
Jacobsen J; Grankvist K; Rasmuson T; Ljungberg B
BJU Int; 2006 May; 97(5):1102-8. PubMed ID: 16643499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
